Pharma channel feed – Endpoints News

Pharma channel feed

Next-generation sequencing: FDA offers guidance to streamline path to market

8 years ago

Does the FDA’s ‘breakthrough’ drug program need to be reformed? Harvard skeptics say yes

8 years ago

Biotech M&A is ripping along now as IPOs surge and venture cash flows. Who's the next big target?

8 years ago

Amgen goes back to Rhode Island to build its first next-gen manufacturing site in the US

8 years ago

More than 2 years after the ugly roci debacle, Clovis says that the SEC is prepping civil charges

8 years ago

Biotech resurrects a long faded Novartis cancer drug star, using a biomarker strategy to push ahead

8 years ago

Pfizer heads to the Hudson, signs 20-year lease at posh new NYC headquarters

8 years ago

AstraZeneca licenses Ionis' NASH drug for $30M as momentum builds in the field

8 years ago

Novartis CEO Vas Narasimhan cuts loose an old anchor and sets sail with $8.7B AveXis buyout

8 years ago

Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal

8 years ago

Celltrion receives CRLs for Rituxan, Herceptin biosimilars

8 years ago

EMA hands Italy's Chiesi a win in its long campaign to advance new drugs for rare diseases

8 years ago

$21B or bust! AbbVie ensures its blockbuster US marathon on Humira will run into 2023

8 years ago

Boehringer Ingelheim is thinking in blockbuster terms as it throws its hat into the ever-widening CD47 ring

8 years ago

Biotech gains ground in NYC: Sprawling research center planned in $1.6B Midtown project

8 years ago

Riding a wave of positive PhIII readouts, Pfizer gets a snap review for lung cancer drug dacomitinib

8 years ago

Institutional research is flawed. I'm teaming with Endpoints to help democratize it

8 years ago

Publisher's note

Roche grabs a remyelination MS drug from Versant as the research team spins out into a $25M regenerative med startup

8 years ago

Eli Lilly jumps into a $473M hunt with Sigilon for the Holy Grail in diabetes cell therapies

8 years ago

Eli Lilly hands transpacific biotech upstart Terns pieces to an experimental NASH puzzle

8 years ago

FDA dismisses Alkermes’ pitch on ‘5461, demanding new depression trials in a damaging setback

8 years ago

After a makeover and hiring spree, China's drug agency is romping and stomping on new reviews and approvals

8 years ago

Could Takeda pull off a $50B-plus Shire takeover? Maybe, but analysts and investors have their doubts if they should

8 years ago

In a bitter brawl, Arcturus details ex-CEO's alleged misconducts in lawsuit and open letter

8 years ago

First page Previous page 300 301 302303304 305 306 Next page Last page